Ordering Recommendation

Prognostication in core-binding factor-related (CBF) AML.

Methodology

Capillary Electrophoresis

Performed

Varies

Reported

8-14 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA)  or green (Sodium heparin) whole blood or bone marrow.

Specimen Preparation

Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Do not freeze. Transport 3 mL bone marrow (Min: 1 mL).

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma, serum, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.

Remarks
Stability

Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable

Reference Interval

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81272

Components

Component Test Code* Component Chart Name LOINC
2002439 Kit Mutations in AML 55201-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • CBF AML testing
  • CKIT
  • Exon 8 and 17
  • GST8
  • KIT ex 8
  • KIT exon 8
KIT Mutations in AML by Fragment Analysis and Sequencing